AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns

Robert J. Lake1.02K FollowersFollow5ShareSavePlay(22min)CommentsSummaryAstraZeneca remains a long-term buy, driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly stretched.AZN's 2025 results showed 8% revenue and 11% EPS growth, with oncology (44% of revenue) and rare diseases as key growth engines.Patent expirations for Farxiga and price pressures in China pose near-term headwinds, but pipeline innovation and emerging market growth underpin future prospects.While AZN trades at a premium relative to peers and its own historical ranges, I expect near-term mean reversion but continued long-term outperformance versus the S&P500. Robert Way/iStock Editorial via Getty Images Founded in 1999 and based in Cambridge, UK, AstraZeneca (AZN) is one of the world’s leading biopharmaceutical companies, ranked 5th by current market cap (at $310 billion) behind Eli Lilly (This article was written byRobert J. Lake1.02K FollowersFollowI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating wealth is the slow accumulation of high quality assets, and the key to enjoying the process of investing is to mix this steady approach with some high risk/high reward opportunities, underappreciated turnaround plays, and transformative technologies. I invest with integrity, only putting my money into companies and industries that aim to make the world a better place.I would consider myself an amateur investor, entirely self-taught with no formal education in investing or business, but smart at figuring out who is worth listening to. I read widely and embrace the notion that my own growth comes from learning from others. In my other life, I have been teaching at the college/university level for over 20 years. I have a PhD from Brunel University and am an accomplished academic writer and editor.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.